期刊文献+

c-kit、c-erbB-2蛋白在卵巢浆液性肿瘤中的表达及其意义 被引量:1

下载PDF
导出
摘要 目的:研究c-kit、c-erbB-2蛋白在卵巢浆液性肿瘤中的表达,为今后可能的分子靶向治疗提供实验依据。方法:应用免疫组织化学SP法检测c-kit、c-erbB-2蛋白在61例卵巢浆液性肿瘤组织的石蜡切片中的表达。结果:c-kit、c-erbB-2蛋白阳性表达率在卵巢浆液性囊腺瘤、交界性卵巢浆液性囊腺瘤、卵巢浆液性囊腺癌中分别为0%和0%、25%和33.3%、63.2%和71.0%。c-kit、c-erbB-2蛋白的阳性表达在卵巢浆液性囊腺瘤与卵巢浆液性囊腺癌之间,交界性卵巢浆液性囊腺瘤与卵巢浆液性囊腺癌之间的有显著性差异(P<0.05);在卵巢浆液性囊腺癌不同病理学分级、临床分期之间的有显著性差异(P<0.05);c-kit蛋白与c-erbB-2的表达有正相关性。结论:c-kit、c-erbB-2蛋白表达上调,提示卵巢浆液性肿瘤进展;c-kit、c-erbB-2蛋白与卵巢浆液性囊腺癌的病理分级、临床分期相关,其表达量增高可能与肿瘤的侵袭相关。
出处 《中国医药导报》 CAS 2007年第01X期53-54,共2页 China Medical Herald
  • 相关文献

参考文献1

二级参考文献15

  • 1Liu Y, Chiriva-Internati M, You C, et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-selfcytotoxic T lymphocytes by recombinant adeno-associated virusbased gene loading of dendritic cells [ J ]. Cancer Gene Ther,2005,12(3) :304 - 312.
  • 2Midgley R, Kerr DJ, Mirza N, et al. A phase Ⅱ dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC) [J]. Proc Am Soc Clin Oncol,2002,21:23b.
  • 3Chang JWC,Hsieh JJ,Chen J S, et al. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-treated melanoma apoptotic cells for patients with malignant melanoma [ J ]. ProcAm Soc Clin Oncol,2002,21:3b.
  • 4Chiriva-Internati M, Liu Y, Salati E, et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells[J ]. Eur J Immunol, 2002,32(1) :30 - 38.
  • 5Slichenmyer WJ,Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases[J]. Semin Oncol, 2001,28 (Suppl 16) :S67 - S79.
  • 6Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as firstline and maintenance therapy for patients with indolent nonhodgkin's lymphoma[J]. J Clin Oncol,2002,20(20):4261 -4267.
  • 7Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer[J]. Clin Colorectal Cancer ,2003,2(4): 246 - 251.
  • 8Goodman L. Persistance-luck-Avastin[J]. J Clin Invest,2004, 113(7) :934 - 940.
  • 9Van Oosterom AT, Judson I, Verweij J, et al. STI 571, an active drug in metastatic gastro-intestinal stromal tumors (GIST), an EORTC phase Ⅰ study[J]. Proc Am Soc Clin Oncol,2001,20 : 1 a.
  • 10Fukuora M, Yano S, Giaccone G, et al. Final results from a phase Ⅱ trial of ZD1839(Iressa) for patients with advanced non-smallcell lung cancer ( IDEAL. 1 ) [ J ]. Proc Am Soc Clin Oncol, 2003,22: 298a.

共引文献17

同被引文献4

  • 1[1]Jemal A,Murray T,Samules A,et al.Canser Statistics[J].CA Causer J Clin,2003,53:5~26.
  • 2[2]Manlik G,Kijima T,Salgia R Role of receptor tyresine kimase in lung cencer[J].Methods Mol Med,2003,74(1):113.
  • 3[3]Slamon DJ,Godolphin W,Jones LA,et al.Studies of the Her-2/neu proto-oneogene in human breast and ovavian cencer[J].Science,1989,244:707~712.
  • 4[4]A nreder MB,Freeman SM,Merogi A,et al.P53,c-erbB-2 and PCNA status in benign,proliferative and maligant ovarian surface epithelial neoplasms,a study of 75 Cases[J].Arch Pathol lab Med,1999,123(4):310~331.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部